...
首页> 外文期刊>World Journal of Surgical Oncology >Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis
【24h】

Safety and feasibility of pressurized intraperitoneal aerosol chemotherapy (PIPAC) associated with systemic chemotherapy: an innovative approach to treat peritoneal carcinomatosis

机译:加压腹膜内气雾化学疗法(PIPAC)与全身性化疗相关联的安全性和可行性:一种治疗腹膜癌的创新方法

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a new treatment that applies chemotherapeutic drugs into the peritoneal cavity as an aerosol under pressure. It improves local bioavailability of chemotherapeutic drugs as compared with conventional intraperitoneal chemotherapy. It has been proved to be safe and feasible if performed as an exclusive treatment in patients affected by peritoneal carcinomatosis. The first results in patients treated with PIPAC associated with systemic chemotherapy are presented. Methods Between June 2015 and February 2016, 57 PIPAC applications with oxaliplatin or cisplatin?+?doxorubicin every 6?weeks at 37?°C and 12?mmHg for 30?min were performed. Forty PIPAC procedures performed in 14 patients were included in this study; thirteen patients were undergoing systemic chemotherapy with a wash-out interval of at least 2?weeks before and 1?week after each PIPAC. Safety, tolerability, and postoperative complications were assessed by collection of adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) 2. Results Forty PIPAC administrations were performed in 14 patients with no major perioperative complications. CTCAE grades 1 and 2 were observed after six and eight procedures, respectively, for abdominal pain and nausea. Renal and hepatic functions were not impaired; no cumulative renal toxicity was observed after repeated PIPAC procedures in association with systemic chemotherapy. Conclusions These preliminary data show that the association of PIPAC and systemic chemotherapy does not induce significant hepatic and renal toxicity. It allows inclusion of patients with extraperitoneal disease or at a high risk of developing it. Further studies are needed to assess whether this combination therapy could become part of the standard treatment for peritoneal carcinomatosis.
机译:背景技术加压腹膜内气雾化学疗法(PIPAC)是一种新的治疗方法,它在压力下将化学治疗药物作为气雾剂应用到腹膜腔中。与传统的腹膜内化疗相比,它提高了化疗药物的局部生物利用度。如果对腹膜癌病患者进行独家治疗,则已被证明是安全可行的。给出了PIPAC联合全身化学疗法治疗的患者的初步结果。方法在2015年6月至2016年2月之间,每6周一次在37°C和12 µmmHg下进行30分钟的57例PIPAC含奥沙利铂或顺铂+阿霉素的应用。本研究包括对14例患者进行的40次PIPAC手术; 13名患者正在接受全身化疗,每次PIPAC的洗净间隔至少为2周前和1周后。根据不良事件通用术语标准(CTCAE)2,通过收集不良事件来评估安全性,耐受性和术后并发症。结果对14例无重大围手术期并发症的患者进行了40次PIPAC给药。经过六次和八次手术后,分别观察到CTCAE 1级和2级腹部疼痛和恶心。肾和肝功能未受损;反复PIPAC联合全身化疗后未观察到累积的肾脏毒性。结论这些初步数据表明PIPAC与全身化学疗法的结合不会引起明显的肝肾毒性。它可以将腹膜外疾病或发展为高风险的患者包括在内。需要进一步的研究来评估这种联合疗法是否可以成为腹膜癌标准疗法的一部分。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号